Divine Aleru, Microbiome Signatures Research Coordinator

This review maps advances in ovarian cancer management, from surgery and chemotherapy to targeted and emerging therapies, and highlights a need to integrate microbiome insights.

This review analyzes the global epidemiology and risk factors of ovarian cancer, emphasizing the role of genetic predispositions, reproductive factors, and lifestyle choices. It highlights the disparities in incidence and mortality rates across regions and calls for better prevention and early detection strategies.

This review discusses ovarian cancer diagnosis, molecular characteristics, and treatment strategies, emphasizing the role of targeted therapies like ARP inhibitors and immunotherapy, with a focus on personalized treatment approaches based on genetic and molecular tumor profiles.

This review covers the epidemiology, genetics, and molecular mechanisms of ovarian cancer, focusing on the role of estrogen receptors and genetic mutations such as RCA1/2. It emphasizes the importance of genetic testing and the potential of targeted therapies, including ARP inhibitors, for improving patient outcomes.

This review discusses liquid biopsy techniques for early ovarian cancer detection, focusing on circulating tumor cells, cell-free NA, and extracellular vesicles. It highlights their potential to improve sensitivity, specificity, and prognosis prediction, providing a promising avenue for non-invasive cancer screening.

This review explores the molecular mechanisms of ovarian cancer metastasis, focusing on the role of stromal cells and the metastatic routes—passive dissemination and hematogenous spread—while discussing therapeutic implications for targeting both cancer cells and the tumor microenvironment.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study explored the role of hormone replacement therapy (RT) in reversing gut microbiome and serum metabolome alterations in women with premature ovarian insufficiency (OI), identifying potential therapeutic targets for microbiome-based interventions.

This review explores butyrate’s role as a modulator in gynecological diseases, including COS, endometriosis, and cancer, highlighting its potential as a therapeutic agent through immune modulation, inflammation reduction, and cancer inhibition.

This paper explores how gut microbiota dysbiosis contributes to premature ovarian failure (OF) and highlights potential therapeutic interventions targeting M for better management of OF.